Back to News
Market Impact: 0.2
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Source: businesswire.com
Healthcare & Biotech
Seaport Therapeutics, a PureTech founded entity, dosed the first patient in its Phase 2a GlyphAgo trial for generalized anxiety disorder and sleep disturbance. The announcement marks the start of the trial; no efficacy results or additional trial details were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
PRTC0.30
SPTX0.70
More News
- Seaport Therapeutics doses first patient in anxiety trial
- PureTech Health gets Panmure Liberum ‘buy' on value and cash returns
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results